Bone Healing During Ninlaro Exposure

Summary

The primary purpose of this study is to investigate if treatment with Ixazomib in multiple myeloma (MM) can strengthen the bones, thus making it resilient to future fractures. Ixazomib will be given at a time point when the disease is in a stable phase, decreasing the likelihood that the potential bone anabolic effect will be abrogated by catabolic effect of active MM. In order to be included in the study, the patient must have treatment demanding MM, and the disease must have been brought into at least partial remission with chemotherapy before inclusion. Moreover, the patient must have pathological bone structure on low dose CT due to the pre-existing disease.

Timeline

Start

2019-10-24

Primary completion

2024-04-01

Completion

2024-04-01

Publications

• Levring MB, Diaz-delCastillo M, Gundesen MT, Cedile O, Andersen CW, Nielsen AL, Moller HEH, Vinholt PJ, Asmussen JT, Kristensen IB, Nyvold CG, Kassem M, Abildgaard N, Andersen TL, Lund T. Ixazomib treatment has a dual effect on bone remodeling in patients with multiple myeloma: follow-up results from a phase 2 clinical study. Bone. 2025 Dec;201:117660. doi: 10.1016/j.bone.2025.117660. Epub 2025 Sep 23.

Drugs

Indications